Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Diabetes & Metabolism

• Publication date

  2000-12-01

• Fields of study

  Medicine

• Identifiers
  PMID 11173719
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

  2000cited by this paper
• Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.

  1999cited by this paper
• Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group.

  1999cited by this paper
• Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. The Insulin Resistance Atherosclerosis Study (IRAS).

  1999cited by this paper
• Glucose intolerance and 23-year risk of coronary heart disease and total mortality: the Honolulu Heart Program.

  1999cited by this paper
• The human insulin analogue insulin lispro.

  1998cited by this paper
• Nighttime Insulin Kinetics and Glycemic Control in Type 1 Diabetes Patients Following Administration of an Intermediate-Acting Lispro Preparation

  1997cited by this paper
• Reduction of Postprandial Hyperglycemia and Frequency of Hypoglycemia in IDDM Patients on Insulin-Analog Treatment

  1997cited by this paper
• Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

  1997cited by this paper
• Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.

  1997cited by this paper
• Postprandial Lipoproteins in Non‐insulin‐dependent Diabetes Mellitus

  1997cited by this paper
• Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up

  1996cited by this paper
• Interval between insulin injection and breakfast in diabetes.

  1994cited by this paper
• Interval between insulin injection and eating in relation to blood glucose control in adult diabetics.

  1985cited by this paper
• THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS.

  1965cited by this paper

• Saudi Consensus for Low-Premixed Insulin Analogues in Type 2 Diabetes: Consensus Report

  2021cites this paper
• Differences in Clinical Outcomes between Patients with and without Hypoglycemia during Hospitalization: A Retrospective Study Using Real-World Evidence

  2020cites this paper
• Switching from Biphasic Human Insulin to Premix Insulin Analogs: A Review of the Evidence Regarding Quality of Life and Adherence to Medication in Type 2 Diabetes Mellitus

  2016cites this paper
• Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs

  2013cites this paper
• Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data

  2012cites this paper
• Premixed Insulin Analogues for the Treatment of Diabetes Mellitus

  2012influential citation
• Intensifying Insulin Therapy with Insulin Analog Premixes: Transitioning from Basal Insulin in Type 2 Diabetes

  2012cites this paper
• Insulin Lispro

  2012cites this paper
• A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

  2011cites this paper
• Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes.

  2011cites this paper
• The 3 R's of managing seniors with type 2 diabetes: recognition, risk, and remedies.

  2009cites this paper
• Importance of Postprandial Glucose Levels as a Target for Glycemic Control in Type 2 Diabetes

  2009cites this paper
• Systematic Review: Comparative Effectiveness and Safety of Premixed Insulin Analogues in Type 2 Diabetes

  2008cites this paper
• Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues.

  2005cites this paper
• Review of Insulin Therapy

  2004cites this paper
• Update on insulin analogues

  2004cites this paper
• Use of the rapid acting insulin analogue lispro and its protamine retarded form (Humalog Mix 25) in a clinical setting

  2004cites this paper
• NEW TRENDS IN INSULIN THERAPY

  2003cites this paper
• Importance of premeal injection time in insulin therapy: Humalog Mix25 is convenient for improved post-prandial glycemic control in type 2 diabetic patients with Italian dietary habits

  2003cites this paper
• A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan.

  2003cites this paper
• Using new insulin strategies in the outpatient treatment of diabetes: clinical applications.

  2003cites this paper
• New insulins in the treatment of diabetes mellitus.

  2002cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mixtures

  2002cites this paper
• Management of Diabetes Mellitus Defining the Role of Insulin Lispro Mix75/25 (Humalog ® Mix75/25™)

  2001cites this paper
• [Present and future of insulin therapy in type 2 diabetic patients].

  2001cites this paper
• Management of Diabetes Mellitus

  2001cites this paper